Miromatrix Medical Inc. (NASDAQ:MIRO – Get Rating) shares traded down 3.6% during mid-day trading on Monday . The company traded as low as $3.26 and last traded at $3.26. 732 shares were traded during mid-day trading, a decline of 95% from the average session volume of 13,489 shares. The stock had previously closed at $3.38.
Analysts Set New Price Targets
Separately, Piper Sandler increased their target price on Miromatrix Medical from $8.00 to $9.00 and gave the stock an "overweight" rating in a report on Monday, November 14th.
Get
Miromatrix Medical alerts:
Miromatrix Medical Trading Down 3.6 %
The firm has a 50 day simple moving average of $3.65 and a 200 day simple moving average of $3.55. The company has a debt-to-equity ratio of 0.10, a quick ratio of 8.09 and a current ratio of 8.09. The firm has a market cap of $68.13 million, a P/E ratio of -2.35 and a beta of -0.35.
Miromatrix Medical (NASDAQ:MIRO – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.04). Miromatrix Medical had a negative return on equity of 65.37% and a negative net
margin of 91,903.22%. The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.01 million. On average, equities research analysts predict that Miromatrix Medical Inc. will post -1.48 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Envestnet Asset Management Inc. purchased a new stake in Miromatrix Medical during the second quarter valued at $54,000. Legacy Wealth Asset Management LLC bought a new position in shares of Miromatrix Medical in the second quarter worth about $54,000. State Street Corp bought a new position in Miromatrix Medical during the first quarter valued at approximately $93,000. BlackRock Inc. boosted its stake in Miromatrix Medical by 98.5% during the first quarter. BlackRock Inc. now owns 30,139 shares of the company's stock valued at $119,000 after buying an additional 14,958 shares during the last quarter. Finally, Merit Financial Group LLC bought a new position in Miromatrix Medical during the fourth quarter valued at approximately $182,000. 16.87% of the stock is owned by institutional investors.
Miromatrix Medical Company Profile
(Get Rating)
Miromatrix Medical Inc, a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells.
Further Reading
- Get a free copy of the StockNews.com research report on Miromatrix Medical (MIRO)
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- Why Warner Bros Discovery Is the S&P's Hottest Stock
- Pinterest is the Social Commerce Platform to Watch in 2023
- 4 High-Yield Dividend Kings For 2023
- Will 2023 be a Good Year for Goodyear Tire Stock?
Receive News & Ratings for Miromatrix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miromatrix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
